Apollomics Reports First Half 2023 Financial Results and
Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half...
Source: globenewswire.com
Apollomic Class News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Apollomic Class. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.